Keywords: xatral, od, filed, marketing, approval, french, drugmaker
Xatral OD filed for US marketing approval
Article | 23 January 2001
French drugmaker Sanofi-Synthelabo has applied for marketing approval inthe USA for Xatral OD (alfuzosin 10mg), a sustained-release once-daily formulation of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
